| Keywords: |
adult; controlled study; event free survival; aged; middle aged; major clinical study; genetics; mutation; histone deacetylase inhibitor; clinical trial; fatigue; cancer recurrence; diarrhea; drug withdrawal; letter; multiple cycle treatment; phase 2 clinical trial; neoplasm recurrence, local; nausea; antineoplastic activity; rash; nonhodgkin lymphoma; lymphoma, non-hodgkin; epigenetics; epigenesis, genetic; tumor recurrence; vorinostat; genetic screening; genetic epigenesis; panobinostat; follicular lymphoma; molecularly targeted therapy; mocetinostat; e1a associated p300 protein; overall response rate; e1a-associated p300 protein; diffuse large b cell lymphoma; histone acetyltransferase; ep300 protein, human; creb-binding protein; cyclic amp responsive element binding protein binding protein; high throughput sequencing; gain of function mutation; refractory disease; abexinostat; very elderly; humans; human; male; female; crebbp protein, human; tazemetostat; monoclonal antibody therapy; ecog performance status; chemiluminescence immunoassay
|
